Neonatal myasthenia gravis (Q88652): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (6 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
Miastenia Gravis Neonatal (MG) refere-se à síndrome clínica de MG causada por autoanticorpos maternos transferidos passivamente para o recém-nascido. Este mecanismo da doença foi descrito para todas as três formas principais de MG, incluindo anticorpos contra receptor de acetilcolina, contra quinase muscular específica e da síndrome miastênica de Lambert-Eaton. A frequência é de 10-30%. Os neonatos apresentam fraqueza, hipotonia, depressão respiratória. Os sintomas diminuem em cerca de 1 a 4 semanas. | |||||||||||||||
| description / en | description / en | ||||||||||||||
Neonatal Myasthenia Gravis (MG) refers to the clinical MG syndrome caused by passively transferred maternal auto-antibodies to the newborn. This disease mechanism has been described for all three major forms of MG, including Acetylcholine receptor, Muscle-specific kinase and Lambert-Eaton myasthenic syndrome antibodies. Frequency is 10-30%. The neonates present with weakness, hypotonia, respiratory depression. The symptoms subside over 1 to 4 weeks. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/1274860004 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:ID_1274860004 | |||||||||||||||
| Property / CURIE: CID11:ID_1274860004 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-ID_1274860004 | |||||||||||||||
| Property / Canary Token: dki-india-ID_1274860004 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 14:59, 15 August 2026
Neonatal Myasthenia Gravis (MG) refers to the clinical MG syndrome caused by passively transferred maternal auto-antibodies to the newborn. This disease mechanism has been described for all three major forms of MG, including Acetylcholine receptor, Muscle-specific kinase and Lambert-Eaton myasthenic syndrome antibodies. Frequency is 10-30%. The neonates present with weakness, hypotonia, respiratory depression. The symptoms subside over 1 to 4 weeks.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_1274860004 |
||
| English | Neonatal myasthenia gravis |
Neonatal Myasthenia Gravis (MG) refers to the clinical MG syndrome caused by passively transferred maternal auto-antibodies to the newborn. This disease mechanism has been described for all three major forms of MG, including Acetylcholine receptor, Muscle-specific kinase and Lambert-Eaton myasthenic syndrome antibodies. Frequency is 10-30%. The neonates present with weakness, hypotonia, respiratory depression. The symptoms subside over 1 to 4 weeks. |
Statements
CID11:ID_1274860004
0 references
dki-india-ID_1274860004
0 references
Concluído
0 references
13 August 2026
0 references
